Travere Therapeutics Inc
Open
51.82 -0.59
Overview
Share price change
24h
Min
51.47
Max
53.22
Income | 1.8M -35M |
|---|---|
Sales | 42M 170M |
EPS | -0.37 |
Profit margin | -20.519 |
Employees | 497 |
EBITDA | -24M -33M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +45.64% upside |
Next Earnings | 29 paź 2026 |
|---|
Market Cap | 250M 5.4B |
|---|---|
Previous open | 52.41 |
Previous close | 51.82 |
Travere Therapeutics Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Travere Therapeutics Inc Forecast
Price Target
By TipRanks
45.64% upside
12 Months Forecast
Average 75.917 USD 45.64%
High 90 USD
Low 62 USD
Based on 12 Wall Street analysts offering 12 month price targets forTravere Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
